BR0008329A - Compostos agonistas receptores de dopamina d1, composição farmacêutica e seu uso - Google Patents

Compostos agonistas receptores de dopamina d1, composição farmacêutica e seu uso

Info

Publication number
BR0008329A
BR0008329A BR0008329-1A BR0008329A BR0008329A BR 0008329 A BR0008329 A BR 0008329A BR 0008329 A BR0008329 A BR 0008329A BR 0008329 A BR0008329 A BR 0008329A
Authority
BR
Brazil
Prior art keywords
hydrogen
halogen
dopamine
pharmaceutical composition
receptor agonist
Prior art date
Application number
BR0008329-1A
Other languages
English (en)
Inventor
Gary Tilbrook
Original Assignee
Cenes Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenes Ltd filed Critical Cenes Ltd
Publication of BR0008329A publication Critical patent/BR0008329A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: "COMPOSTOS AGONISTAS RECEPTORES DE DOPAMINA D1, COMPOSIçãO FARMACêUTICA E SEU USO". A invenção fornece 2,3,4,5-tetrahidro-1H-3-benzazepinas de fórmula geral (I) na qual: R^ 1^ é hidrogênio, halogênio, C~ 1~-C~ 4~ alquila, ou CF~ 3~; R^ 2^ é hidrogênio, metila, ou alquenila inferior de 3 a 5 átomos de carbono; R^ 3^ e R^ 4^ juntos formam um anel de furano, díidrofurano, tiofeno, diidrotiofeno, ciclopentano ou ciclohexano e R^ 5~ é hidrogênio ou R^ 4^ e R^ 5~ juntos formam um anel de furano, diidrofurano, tiofeno, diidrotiofeno, ciclopentano ou ciclohexano e R^ 3^ é hidrogênio; R^ 6^ é hidrogênio, halogênio, CF~ 3~, CN, N0~ 2~ ou NH~ 2~; R^ 7^ é hidrogênio, halogênio, CF~ 3~, CN, NO~ 2~ ou NH~ 2~. A combinação específica de substituentes: R~ 1~ = H, R~ 2~= H e R~ 4~ e R~ 5~ juntos formando um anel de ciclohexano é excluído, a saber 1-(5,6,7,8-tetrahidronaftalen- 2-il)- 2,3,4,5-tetrahidro-1 H -benzo[d]azepina- 7,8-diol. Os compostos da invenção fornecem agentes terapêuticos que seletivamente interagem positivamente com receptores de dopamina D1 pós-sinática no estriado, diretamente ou indiretamente (denominados agonistas de dopamina D1) e são particularmente valiosos como agentes anti-Parkinsonianos.
BR0008329-1A 1999-02-17 2000-02-17 Compostos agonistas receptores de dopamina d1, composição farmacêutica e seu uso BR0008329A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903671.7A GB9903671D0 (en) 1999-02-17 1999-02-17 Dopamine D-1 receptor agonist compounds
PCT/GB2000/000570 WO2000049000A1 (en) 1999-02-17 2000-02-17 Dopamine d1 receptor agonist compounds

Publications (1)

Publication Number Publication Date
BR0008329A true BR0008329A (pt) 2002-01-29

Family

ID=10847990

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008329-1A BR0008329A (pt) 1999-02-17 2000-02-17 Compostos agonistas receptores de dopamina d1, composição farmacêutica e seu uso

Country Status (17)

Country Link
EP (1) EP1157009A1 (pt)
JP (1) JP2002537288A (pt)
KR (1) KR20010108228A (pt)
CN (1) CN1142916C (pt)
AU (1) AU767332B2 (pt)
BR (1) BR0008329A (pt)
CA (1) CA2363695A1 (pt)
CZ (1) CZ20012973A3 (pt)
EA (1) EA004745B1 (pt)
GB (1) GB9903671D0 (pt)
HU (1) HUP0200057A3 (pt)
IL (1) IL144810A0 (pt)
MX (1) MXPA01008294A (pt)
NO (1) NO20013978L (pt)
PL (1) PL349838A1 (pt)
WO (1) WO2000049000A1 (pt)
ZA (1) ZA200106478B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130576D0 (en) * 2001-12-20 2002-02-06 Cenes Ltd Dopamine D1 receptor agonist pro-drug compounds & derivatives
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
AU2006278514A1 (en) * 2005-08-03 2007-02-15 Mia Levite Killing human lymphoma and leukemia cancer cells and TCR-activated normal human cells by dopamine D1R agonists
CN101684096A (zh) * 2008-09-23 2010-03-31 中国科学院上海药物研究所 一类新型苯并氮杂卓类化合物及其制备方法和用途
CN102276531A (zh) * 2011-05-30 2011-12-14 扬子江药业集团广州海瑞药业有限公司 一种甲磺酸非诺多泮的制备方法
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561305A (en) * 1975-07-02 1980-02-20 Smithkline Corp Benzazepine derivatives and pharmeceutical compositions containing them
US4111957A (en) * 1977-02-02 1978-09-05 Smithkline Corporation Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4265889A (en) * 1978-05-05 1981-05-05 Smithkline Corporation 6-Lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4707483A (en) * 1985-12-20 1987-11-17 Smithkline Beckman Corporation 1-phenyl-3-benzazepines and their use for treating gastrointestinal motility disorders
US4861771A (en) * 1989-01-27 1989-08-29 Smithkline Beckman Corporation Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine as prodrugs

Also Published As

Publication number Publication date
AU2563200A (en) 2000-09-04
WO2000049000A1 (en) 2000-08-24
ZA200106478B (en) 2002-02-07
HUP0200057A2 (en) 2002-08-28
NO20013978D0 (no) 2001-08-15
CN1341102A (zh) 2002-03-20
NO20013978L (no) 2001-08-15
MXPA01008294A (es) 2002-07-02
AU767332B2 (en) 2003-11-06
EP1157009A1 (en) 2001-11-28
KR20010108228A (ko) 2001-12-07
CN1142916C (zh) 2004-03-24
CZ20012973A3 (cs) 2002-01-16
GB9903671D0 (en) 1999-04-14
IL144810A0 (en) 2002-06-30
EA004745B1 (ru) 2004-08-26
HUP0200057A3 (en) 2004-03-29
PL349838A1 (en) 2002-09-23
CA2363695A1 (en) 2000-08-24
EA200100783A1 (ru) 2002-02-28
JP2002537288A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
BR0010348A (pt) Uso de antagonistas seletivos de receptor <244>~ 1b~-adrenérgico para aperfeiçoamento de disfunção sexual
EA200300453A1 (ru) Производные 3-ароилиндола и их применение в качестве агонистов рецепторов cb2
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BR0115436A (pt) Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina
BR0115478A (pt) Aminotiazós e o uso dos mesmos como antagonistas do receptor da adenosina
BR0309106A (pt) Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm
RS39704A (sr) Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
AR006545A1 (es) Compuestos sustitutos de las catecolaminas, utiles como antagonistas beta3, composiciones farmaceuticas que los contienen y compuestos intermediarios deaplicacion exclusiva en la preparacion de dichos compuestos
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0111019A (pt) 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptores muscarìnicos
EA200200646A1 (ru) Соединения мочевины, обладающие активностью антагонистов мускариновых рецепторов
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
PE20061327A1 (es) Combinaciones de derivados de benzofurano y un antidepresivo para el tratamiento o la prevencion de la depresion
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
BRPI0506139A (pt) derivados fluoreno
EA200300519A1 (ru) Соединения производных бензотиофена, способ их получения и применения
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
BR0009278A (pt) 1-arenossulfonil-2-aril-pirrolidina e derivados depiperidina
BR0014808A (pt) Processos de preparação de um composto, e, compostos nitroaromáticos
BR0008329A (pt) Compostos agonistas receptores de dopamina d1, composição farmacêutica e seu uso
HK1074843A1 (en) Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0317222A (pt) Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: SHIRE PHARMACEUTICAL DEVELOPMENT LIMITED (GB)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.